Serum lipids in epileptic children treated with carbamazepine and valproate
Serum total cholesterol (TC), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C) and very low-density lipoprotein cholesterol, triglyceride, apolipoproteins A1 and B levels were studied in 57 healthy children and in 39 children with epilepsy who had been receiving carbamazepine (CBZ)...
Gespeichert in:
| Veröffentlicht in: | European journal of pediatrics 1997-07, Vol.156 (7), p.565-567 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 567 |
|---|---|
| container_issue | 7 |
| container_start_page | 565 |
| container_title | European journal of pediatrics |
| container_volume | 156 |
| creator | SÖZÜER, D. T ATAKLI, D DOGU, O BAYBAS, S ARPACI, B |
| description | Serum total cholesterol (TC), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C) and very low-density lipoprotein cholesterol, triglyceride, apolipoproteins A1 and B levels were studied in 57 healthy children and in 39 children with epilepsy who had been receiving carbamazepine (CBZ) (23 children) for 1.58 +/- 1.10 years or valproic acid (VPA) (16 children) for 1.34 +/- 1.11 years. In patients receiving CBZ, mean TC level, mean LDL-C level, mean TC/HDL-C ratio and mean LDL-C/HDL-C ratio-were significantly higher than controls. None of the mean levels of serum lipids evaluated in patients receiving VPA was significantly different from the corresponding control group mean. Changes in serum lipids correlated with neither duration of therapy or plasma antiepileptic levels nor age or gender.
Our results suggested that CBZ, a hepaticenzyme-inducing drug, affects serum lipid status. Long-term prospective studies are necessary to determine whether chronic CBZ therapy is a risk factor for atherosclerotic disorders. |
| doi_str_mv | 10.1007/s004310050664 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79168775</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79168775</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-b44a11295986f548898756f004db8664304b5b588fe118a2f251d9bd6b00878f3</originalsourceid><addsrcrecordid>eNpd0EtLxDAUBeAgyjiOLl0KQcRd9ebRNFnK4AsHXKjrkrYJk6Evk1bRX29kyoCuErgfNzkHoVMCVwQguw4AnMVbCkLwPTQnnNGEQCb20RwYh0QQpQ7RUQgbiF4ROUMzRaPibI6eXowfG1y73lUBuxab3tWmH1yJy7WrK29aPHijB1PhTzescal9oRv9HV1rsG4r_KHr3ndRHKMDq-tgTqZzgd7ubl-XD8nq-f5xebNKSsb5kBSca0KoSpUUNuVSKpmlwsYYVSFjBga8SItUSmsIkZpampJKFZUoAGQmLVugy-3e-Oz7aMKQNy6Upq51a7ox5DGjkFmWRnj-D2660bfxbzmlRFEKUkSUbFHpuxC8sXnvXaP9V04g_204_9Nw9GfT0rFoTLXTU6VxfjHNdSh1bb1uSxd2jGaEASj2A6xtgII</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>221922086</pqid></control><display><type>article</type><title>Serum lipids in epileptic children treated with carbamazepine and valproate</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>SÖZÜER, D. T ; ATAKLI, D ; DOGU, O ; BAYBAS, S ; ARPACI, B</creator><creatorcontrib>SÖZÜER, D. T ; ATAKLI, D ; DOGU, O ; BAYBAS, S ; ARPACI, B</creatorcontrib><description>Serum total cholesterol (TC), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C) and very low-density lipoprotein cholesterol, triglyceride, apolipoproteins A1 and B levels were studied in 57 healthy children and in 39 children with epilepsy who had been receiving carbamazepine (CBZ) (23 children) for 1.58 +/- 1.10 years or valproic acid (VPA) (16 children) for 1.34 +/- 1.11 years. In patients receiving CBZ, mean TC level, mean LDL-C level, mean TC/HDL-C ratio and mean LDL-C/HDL-C ratio-were significantly higher than controls. None of the mean levels of serum lipids evaluated in patients receiving VPA was significantly different from the corresponding control group mean. Changes in serum lipids correlated with neither duration of therapy or plasma antiepileptic levels nor age or gender.
Our results suggested that CBZ, a hepaticenzyme-inducing drug, affects serum lipid status. Long-term prospective studies are necessary to determine whether chronic CBZ therapy is a risk factor for atherosclerotic disorders.</description><identifier>ISSN: 0340-6199</identifier><identifier>EISSN: 1432-1076</identifier><identifier>DOI: 10.1007/s004310050664</identifier><identifier>PMID: 9243243</identifier><identifier>CODEN: EJPEDT</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adolescent ; Age ; Analysis of Variance ; Anticonvulsants - pharmacology ; Anticonvulsants - therapeutic use ; Apolipoproteins ; Apolipoproteins - blood ; Atherosclerosis ; Biological and medical sciences ; Carbamazepine - pharmacology ; Carbamazepine - therapeutic use ; Case-Control Studies ; Child ; Child, Preschool ; Cholesterol ; Cholesterol - blood ; Enzymes ; Epilepsy ; Epilepsy - drug therapy ; Female ; Gender ; Hematology ; High density lipoprotein ; Humans ; Investigative techniques, diagnostic techniques (general aspects) ; Lipids ; Lipids - blood ; Lipoproteins ; Male ; Medical sciences ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Triglycerides - blood ; Valproic Acid - pharmacology ; Valproic Acid - therapeutic use</subject><ispartof>European journal of pediatrics, 1997-07, Vol.156 (7), p.565-567</ispartof><rights>1997 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-b44a11295986f548898756f004db8664304b5b588fe118a2f251d9bd6b00878f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2713009$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9243243$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SÖZÜER, D. T</creatorcontrib><creatorcontrib>ATAKLI, D</creatorcontrib><creatorcontrib>DOGU, O</creatorcontrib><creatorcontrib>BAYBAS, S</creatorcontrib><creatorcontrib>ARPACI, B</creatorcontrib><title>Serum lipids in epileptic children treated with carbamazepine and valproate</title><title>European journal of pediatrics</title><addtitle>Eur J Pediatr</addtitle><description>Serum total cholesterol (TC), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C) and very low-density lipoprotein cholesterol, triglyceride, apolipoproteins A1 and B levels were studied in 57 healthy children and in 39 children with epilepsy who had been receiving carbamazepine (CBZ) (23 children) for 1.58 +/- 1.10 years or valproic acid (VPA) (16 children) for 1.34 +/- 1.11 years. In patients receiving CBZ, mean TC level, mean LDL-C level, mean TC/HDL-C ratio and mean LDL-C/HDL-C ratio-were significantly higher than controls. None of the mean levels of serum lipids evaluated in patients receiving VPA was significantly different from the corresponding control group mean. Changes in serum lipids correlated with neither duration of therapy or plasma antiepileptic levels nor age or gender.
Our results suggested that CBZ, a hepaticenzyme-inducing drug, affects serum lipid status. Long-term prospective studies are necessary to determine whether chronic CBZ therapy is a risk factor for atherosclerotic disorders.</description><subject>Adolescent</subject><subject>Age</subject><subject>Analysis of Variance</subject><subject>Anticonvulsants - pharmacology</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Apolipoproteins</subject><subject>Apolipoproteins - blood</subject><subject>Atherosclerosis</subject><subject>Biological and medical sciences</subject><subject>Carbamazepine - pharmacology</subject><subject>Carbamazepine - therapeutic use</subject><subject>Case-Control Studies</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cholesterol</subject><subject>Cholesterol - blood</subject><subject>Enzymes</subject><subject>Epilepsy</subject><subject>Epilepsy - drug therapy</subject><subject>Female</subject><subject>Gender</subject><subject>Hematology</subject><subject>High density lipoprotein</subject><subject>Humans</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Lipids</subject><subject>Lipids - blood</subject><subject>Lipoproteins</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Triglycerides - blood</subject><subject>Valproic Acid - pharmacology</subject><subject>Valproic Acid - therapeutic use</subject><issn>0340-6199</issn><issn>1432-1076</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0EtLxDAUBeAgyjiOLl0KQcRd9ebRNFnK4AsHXKjrkrYJk6Evk1bRX29kyoCuErgfNzkHoVMCVwQguw4AnMVbCkLwPTQnnNGEQCb20RwYh0QQpQ7RUQgbiF4ROUMzRaPibI6eXowfG1y73lUBuxab3tWmH1yJy7WrK29aPHijB1PhTzescal9oRv9HV1rsG4r_KHr3ndRHKMDq-tgTqZzgd7ubl-XD8nq-f5xebNKSsb5kBSca0KoSpUUNuVSKpmlwsYYVSFjBga8SItUSmsIkZpampJKFZUoAGQmLVugy-3e-Oz7aMKQNy6Upq51a7ox5DGjkFmWRnj-D2660bfxbzmlRFEKUkSUbFHpuxC8sXnvXaP9V04g_204_9Nw9GfT0rFoTLXTU6VxfjHNdSh1bb1uSxd2jGaEASj2A6xtgII</recordid><startdate>19970701</startdate><enddate>19970701</enddate><creator>SÖZÜER, D. T</creator><creator>ATAKLI, D</creator><creator>DOGU, O</creator><creator>BAYBAS, S</creator><creator>ARPACI, B</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>19970701</creationdate><title>Serum lipids in epileptic children treated with carbamazepine and valproate</title><author>SÖZÜER, D. T ; ATAKLI, D ; DOGU, O ; BAYBAS, S ; ARPACI, B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-b44a11295986f548898756f004db8664304b5b588fe118a2f251d9bd6b00878f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adolescent</topic><topic>Age</topic><topic>Analysis of Variance</topic><topic>Anticonvulsants - pharmacology</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Apolipoproteins</topic><topic>Apolipoproteins - blood</topic><topic>Atherosclerosis</topic><topic>Biological and medical sciences</topic><topic>Carbamazepine - pharmacology</topic><topic>Carbamazepine - therapeutic use</topic><topic>Case-Control Studies</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cholesterol</topic><topic>Cholesterol - blood</topic><topic>Enzymes</topic><topic>Epilepsy</topic><topic>Epilepsy - drug therapy</topic><topic>Female</topic><topic>Gender</topic><topic>Hematology</topic><topic>High density lipoprotein</topic><topic>Humans</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Lipids</topic><topic>Lipids - blood</topic><topic>Lipoproteins</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Triglycerides - blood</topic><topic>Valproic Acid - pharmacology</topic><topic>Valproic Acid - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SÖZÜER, D. T</creatorcontrib><creatorcontrib>ATAKLI, D</creatorcontrib><creatorcontrib>DOGU, O</creatorcontrib><creatorcontrib>BAYBAS, S</creatorcontrib><creatorcontrib>ARPACI, B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SÖZÜER, D. T</au><au>ATAKLI, D</au><au>DOGU, O</au><au>BAYBAS, S</au><au>ARPACI, B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum lipids in epileptic children treated with carbamazepine and valproate</atitle><jtitle>European journal of pediatrics</jtitle><addtitle>Eur J Pediatr</addtitle><date>1997-07-01</date><risdate>1997</risdate><volume>156</volume><issue>7</issue><spage>565</spage><epage>567</epage><pages>565-567</pages><issn>0340-6199</issn><eissn>1432-1076</eissn><coden>EJPEDT</coden><abstract>Serum total cholesterol (TC), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C) and very low-density lipoprotein cholesterol, triglyceride, apolipoproteins A1 and B levels were studied in 57 healthy children and in 39 children with epilepsy who had been receiving carbamazepine (CBZ) (23 children) for 1.58 +/- 1.10 years or valproic acid (VPA) (16 children) for 1.34 +/- 1.11 years. In patients receiving CBZ, mean TC level, mean LDL-C level, mean TC/HDL-C ratio and mean LDL-C/HDL-C ratio-were significantly higher than controls. None of the mean levels of serum lipids evaluated in patients receiving VPA was significantly different from the corresponding control group mean. Changes in serum lipids correlated with neither duration of therapy or plasma antiepileptic levels nor age or gender.
Our results suggested that CBZ, a hepaticenzyme-inducing drug, affects serum lipid status. Long-term prospective studies are necessary to determine whether chronic CBZ therapy is a risk factor for atherosclerotic disorders.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>9243243</pmid><doi>10.1007/s004310050664</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-6199 |
| ispartof | European journal of pediatrics, 1997-07, Vol.156 (7), p.565-567 |
| issn | 0340-6199 1432-1076 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79168775 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adolescent Age Analysis of Variance Anticonvulsants - pharmacology Anticonvulsants - therapeutic use Apolipoproteins Apolipoproteins - blood Atherosclerosis Biological and medical sciences Carbamazepine - pharmacology Carbamazepine - therapeutic use Case-Control Studies Child Child, Preschool Cholesterol Cholesterol - blood Enzymes Epilepsy Epilepsy - drug therapy Female Gender Hematology High density lipoprotein Humans Investigative techniques, diagnostic techniques (general aspects) Lipids Lipids - blood Lipoproteins Male Medical sciences Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Triglycerides - blood Valproic Acid - pharmacology Valproic Acid - therapeutic use |
| title | Serum lipids in epileptic children treated with carbamazepine and valproate |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T02%3A48%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20lipids%20in%20epileptic%20children%20treated%20with%20carbamazepine%20and%20valproate&rft.jtitle=European%20journal%20of%20pediatrics&rft.au=S%C3%96Z%C3%9CER,%20D.%20T&rft.date=1997-07-01&rft.volume=156&rft.issue=7&rft.spage=565&rft.epage=567&rft.pages=565-567&rft.issn=0340-6199&rft.eissn=1432-1076&rft.coden=EJPEDT&rft_id=info:doi/10.1007/s004310050664&rft_dat=%3Cproquest_cross%3E79168775%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=221922086&rft_id=info:pmid/9243243&rfr_iscdi=true |